|
|||||
|
|
| 伊立替康联合顺铂治疗小细胞肺癌60例临床观察 | |
| 引用本文： | 赵金波,周金平,刘芳,李丹,方丽萍,乔京京,孙秀华. 伊立替康联合顺铂治疗小细胞肺癌60例临床观察[J]. 实用全科医学, 2011, 9(3): 371-371,393 |
| 作者姓名： | 赵金波 周金平 刘芳 李丹 方丽萍 乔京京 孙秀华 |
| 作者单位： | 大连医科大学附属二院肿瘤科; |
| 摘 要： | 目的观察伊立替康（CPT-11）联合顺铂治疗复发晚期小细胞肺癌的疗效及安全性。方法伊立替康120～180 mg/m2静脉滴注d1,60～80 mg/m2静脉滴注d8;DDP 75 mg/m2静脉滴注d1～3;21 d为一周期。结果 60例均可评价疗效,完全缓解率8.3%（5/60）,部分缓解率为40.0%（24/60）,总有效率CR＋PR为48.3%（29/60）,稳定18例（30.0%）;进展13例（21.7%）。主要毒副反应为血液学毒性和消化道症状,其中Ⅲ、Ⅳ度白细胞减少发生率为50.0%（30/60）;血小板减少发生率为25.0%（15/60）;Ⅲ度血小板减少发生率为3.3%（2/60）;恶心呕吐发生率为80.0%（48/60）,Ⅲ、Ⅳ度发生率为25%（15/60）;腹泻发生率为50.0%（30/60）,其中Ⅲ、Ⅳ度发生率为33.3%（20/60）,全组无毒性相关死亡。结论伊立替康联合顺铂二线治疗复发晚期小细胞肺癌,有效率较高,毒副反应可以耐受。 |
| 关 键 词： | 伊立替康 顺铂 小细胞肺癌 联合化疗 |
The Clinical Observation of Combined Chemotherapy of Irinotecan and Cisplatin in the Treatment of 60 Case of Relapsed Advanced Small Cell Lung Cancer |
|
| ZHAO Jin-bo,ZHOU Jin-ping,LIU Fang,et al.. The Clinical Observation of Combined Chemotherapy of Irinotecan and Cisplatin in the Treatment of 60 Case of Relapsed Advanced Small Cell Lung Cancer[J]. Applied Journal Of General Practice, 2011, 9(3): 371-371,393 | |
| Authors: | ZHAO Jin-bo ZHOU Jin-ping LIU Fang et al. |
| Affiliation: | ZHAO Jin-bo,ZHOU Jin-ping,LIU Fang,et al.Department of Oncology,the Second Affiliated Hospital of DaLian Medical University,Dalian 116023,Liaoning,China |
| Abstract: | Objective The aim of this study was to evaluate the efficacy and safety of the irinotecan and cisplatin combination in relapsed advanced SCLC.Methods Eligible patients with SCLC who had progressed or relapsed after therapy were done with cisplatin and irinotecan.The regimen consisted of irinotecan 120-180 mg/m2 on d1 and 60-80 mg/m2 on d8,cisplatin 75 mg/m2 on d1-3;the plan was given 21 days.Results In 60 evaluable patients,response include 5 complete remissions and 24 partial remissions(overall response ra... |
| Keywords: | Irinotecan Cisplatin SCLC Combined chemotherapy |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ | |